First ophthalmic insert launched

Mydriasert is inserted aseptically using the sterile forceps provided
Mydriasert is inserted aseptically using the sterile forceps provided

Mydriasert (phenylephrine + tropicamide) is a combination of mydriatic agents with a novel method of delivery, indicated for use before surgery or for diagnostic purposes when monotherapy is insufficient. The insert is placed into the conjunctival sac of the affected eye by an appropriately trained healthcare professional.

Compared with eye drops, the insert takes slightly longer to produce mydriasis; however, less nurse intervention may be required and eyesight recovery seems to be more rapid. The insert must be removed 30 minutes after achieving sufficient mydriasis and within 2 hours of insertion.

View Mydriasert drug record

Further Information: Spectrum Thea Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases